The antitrust division of the U.S. Department of Justice has subpoenaed Mylan N.V. for information relating to the pricing and marketing of its generic doxycycline antibiotic products, the drugmaker said on Friday.
The Department of Justice has also sought information on any communication with competitors about the anti-bacterial products, the company said in a regulatory filing, adding it would cooperate with the federal agency.
The nearly 40-year-old antibiotic is used to treat bacterial infections such as acne, pneumonia, Lyme disease, chlamydia and syphilis.
Competitors Endo International and Allergan Inc have also received similar subpoenas, according to regulatory filings made by them in November and August.
U.S. drugmakers have been under increased pressure from the government, insurers and corporations over steep increases in the prices of generic drugs.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Antitrust Lawsuit Over Google’s Search Monopoly Proceeds in CA Court
Jan 20, 2025 by
CPI
Digital Markets Act at Two Years: Enforcement in a Shifting Political Climate
Jan 20, 2025 by
CPI
EU Expands Tech Oversight with Updated Anti-Hate Speech Code
Jan 20, 2025 by
CPI
Cargill Settles Turkey Price-Fixing Lawsuit for $32.5 Million
Jan 20, 2025 by
CPI
DOJ Raises Concerns Over $2.8 Billion NCAA Settlement
Jan 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand